Can a digital medicine system improve adherence to antipsychotic treatment?

A substantial proportion of people with mental health conditions do not adhere to prescribed pharmacological treatments. Poor adherence is probably one of the most critical elements contributing to relapse in people with schizophrenia and other severe mental disorders. In order to tackle this global...

Full description

Saved in:
Bibliographic Details
Published in:Epidemiology and psychiatric sciences 2018-06, Vol.27 (3), p.227-229
Main Authors: Papola, D., Gastaldon, C., Ostuzzi, G.
Format: Article
Language:English
Subjects:
Antipsychotic Agents - therapeutic use
Antipsychotics
Aripiprazole
Aripiprazole - therapeutic use
Bipolar disorder
Epidemiology for Clinical Psychopharmacology
Evidence-Based Practice
FDA approval
Humans
Medication Adherence
Medicine
Mental disorders
Patient compliance
Patients
Pharmaceutical industry
Psychiatry
Psychopharmacology
Psychotic Disorders - drug therapy
Psychotic Disorders - psychology
Psychotropic drugs
Schizophrenia
Sensors
Studies
Telemedicine
United States
United States Food and Drug Administration
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A substantial proportion of people with mental health conditions do not adhere to prescribed pharmacological treatments. Poor adherence is probably one of the most critical elements contributing to relapse in people with schizophrenia and other severe mental disorders. In order to tackle this global issue, in November 2017 the Food and Drug Administration approved a tablet formulation of the atypical antipsychotic aripiprazole embedded with a novel digital adherence-assessment device. In this commentary, we critically appraised the potential beneficial and harmful consequences of this new digital formulation of aripiprazole, and we highlighted expected implications for clinical practice.
ISSN:2045-7960
2045-7979
DOI:10.1017/S2045796018000082